Liquid Biopsy Using Methylation Sequencing for Lung Cancer

Clinical Utility of Circulating Tumor DNA Methylation in the Diagnosis of Primary Lung Cancer

This study aims to investigate the utility of circulating tumor DNA (ctDNA) methylation sequencing in the diagnosis of primary lung cancer.

Plasma sample of patients with and without lung cancer will be collected and analyzed using methylation-sensitive enzyme sequencing method. Diagnostic performance of ctDNA methylation sequencing will be compared with that of tumor markers (CEA, Cyfra 21-1, and NSE) combined.

Inclusion Criteria:

• Lung cancer group

  1. Pathologically proven lung cancer
  2. Clinically suspected lung cancer on chest CT scan

• Benign pulmonary disease group

  • Chronic obstructive pulmonary disease, interstitial lung disease, pneumonia, bronchiectasis, non-tuberculous mycobacterial lung disease, pulmonary vascular disease

Exclusion Criteria:

• Patients with previous history of lung cancer
• Patients who have been diagnosed with other malignancy within 5 years
• Unstable vital status
• Active pulmonary tuberculosis
• Infection with hepatitis B virus (HBV), hepatitis C virus (HCV), or human immunodeficiency virus (HIV)